Table 1. Characteristics of patients with haematopoietic stem cell transplantation (HSCT).
| Total | Male | Female | |
|---|---|---|---|
| No. of patients | 2544 | 1439 | 1105 |
| Person-years at risk | 11 198 | 6075.6 | 5122.8 |
| Median follow-up, years (interquartile range) | 4.46 (2.11–7.75) | 4.21 (2.00–7.65) | 4.82 (2.31–8.05) |
| Median age, years (interquartile range) | 32 (20–45) | 32 (20–45) | 33 (20–46) |
|
Primary disease | |||
| Acute lymphoblastic leukaemia | 293 (11.5%) | 167 (11.6%) | 126 (11.4%) |
| Acute myeloid leukaemia | 867 (34.2%) | 458 (31.8%) | 409 (37.0%) |
| Lymphoma | 678 (26.6%) | 390 (27.1%) | 288 (26.0%) |
| Multiple myeloma | 270 (10.6%) | 172 (12.0%) | 98 (8.9%) |
| Severe aplastic anaemia | 270 (10.6%) | 162 (11.3%) | 108 (9.9%) |
| Thalassaemia | 68 (2.7%) | 30 (2.1%) | 38 (3.4%) |
| Othersa | 98 (3.8%) | 60 (4.1%) | 38 (3.4%) |
|
Treatment | |||
| TBI | 605 (23.8%) | 335 (23.3%) | 270 (24.4%) |
| Pre-HSCT Radiotherapy | 841 (33.1%) | 469 (32.6%) | 372 (33.7%) |
| Allogeneic | 1514 (59.5%) | 836 (58.1%) | 678 (61.3%) |
| Autologous | 1030 (40.5%) | 603 (41.9%) | 427 (38.7%) |
| cGVHD | 751 (49.6%) | 413 (49.4%) | 338 (49.8%) |
|
Immunosupressantsb | |||
| Cyclosporin | 1471 (97.1%) | 805 (96.2%) | 666 (98.2%) |
| Tacrolimus | 138 (9.1%) | 76 (9.1%) | 62 (9.1%) |
| Methylprednisolone | 253 (16.7%) | 134 (16.0%) | 119 (17.5%) |
| Mycophenolate | 253 (16.7%) | 145 (17.3%) | 108 (15.9%) |
| Sirolimus | 36 (2.3%) | 24 (2.8%) | 12 (1.7%) |
| Anti-thymocyte globulin | 381 (25.1%) | 207 (24.7%) | 174 (25.6%) |
| Azathioprine | 254 (16.7%) | 153 (18.3%) | 101 (14.8%) |
| Cyclophosphamide | 31 (2.0%) | 16 (1.9%) | 15 (2.2%) |
| Methotrexate | 41 (2.7%) | 23 (2.7%) | 18 (2.6%) |
|
Comorbidities | |||
| Diabetes mellitus | 265 (10.4%) | 162 (11.3%) | 103 (9.3%) |
| COPD | 311 (12.2%) | 195 (13.6%) | 116 (10.5%) |
| Chronic kidney disease | 255 (10.0%) | 159 (11.0%) | 96 (8.7%) |
| Liver cirrhosis | 48 (1.9%) | 27 (1.9%) | 21 (1.9%) |
| Autoimmune diseases | 152 (6.0%) | 67 (4.7%) | 85 (7.7%) |
| Dyslipidaemia | 309 (12.1%) | 135 (9.4%) | 174 (15.7%) |
|
Age at HSCT, years | |||
| 0–19 | 545 (21.4%) | 302 (21.0%) | 243 (22.0%) |
| 20–39 | 1027 (40.4%) | 567 (39.4%) | 460 (41.6%) |
| 40–59 | 871 (34.2%) | 508 (35.3%) | 363 (32.9%) |
| ⩾60 | 101 (4.0%) | 62 (4.3%) | 39 (3.5%) |
Abbreviations: cGVHD=chronic graft vs host disease; COPD=chronic obstructive pulmonary disease; TBI=total body irradiation.
a
Others: chronic lymphoid leukaemia; chronic myeloid leukaemia; myelodysplastic syndrome.
b
Immunosupressants are only indicated in allo-HSCT.